Hexaware Technologies – ESOP Grant Announcement (April 29 2026)

Key Highlights

• Date of approval: 29 April 2026 (NRC meeting 7:02 PM – 7:35 PM)
• Number of options granted: 193,700
• Exercise price: INR 382.5 per share (face value INR 1)
• Vesting: As per the ESOP 2024 schedule (details not disclosed in the intimation)
• Regulatory compliance: Disclosed under SEBI Listing Regulation 30 and Master Circular HO/49/14/14(7)2025‑CFD‑POD2/I/3762/2026.

Financial Implications

• Potential dilution: If all options are exercised, 193,700 new equity shares will be issued, representing a modest increase in share count relative to Hexaware’s existing share base.
• Cash inflow: Exercise will generate cash at INR 382.5 per share, but this will occur only when/if options are exercised in the future.
• Earnings per share (EPS): No immediate impact; dilution effect on EPS will be realized only post‑exercise.

Strategic Rationale

• Talent retention & motivation: ESOPs are a common tool to align employee interests with shareholders, fostering long‑term commitment.
• Signal of confidence: Management’s willingness to set an exercise price above recent market levels suggests confidence in future share price appreciation.

Regulatory & Compliance Notes

• The announcement complies with SEBI Listing Obligations and Disclosure Requirements (LODR) and the SEBI (SBEB) Regulations, 2021.
• Full details are provided in Annexure A and will be posted on the company’s investor relations portal (www.hexaware.com).

Risks & Opportunities

• Risks: Potential dilution if a large proportion of options are exercised; market perception may be affected if the exercise price is perceived as too high.
• Opportunities: Successful vesting and exercise can bring additional capital and reinforce a performance‑driven culture, potentially supporting revenue growth and profitability.

Investor Takeaway

The ESOP grant is a standard, forward‑looking incentive mechanism with limited immediate financial impact. Investors should keep an eye on future vesting milestones and any subsequent disclosures regarding option exercises, as these will determine the actual dilution and cash‑flow implications.

Prepared on 29 April 2026 based on the company’s statutory intimation.